Compare Enveric Biosciences Inc (ENVB) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $41.82 (market cap $3.80B). The key difference: Vanguard Global ex-US Real Estate Index Fd ETF is far larger — about 558.8× Enveric Biosciences Inc's market cap, and Vanguard Global ex-US Real Estate Index Fd ETF is more actively traded (277,049 versus 64,867). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| ENVB | VNQI | |
|---|---|---|
Market Cap | $6.80M | $3.80B |
Volume | 64,867 | 277,049 |
Sector | Health | — |
52-Week High | $10.80 | $50.76 |
52-Week Low | $1.27 | $41.81 |
Typical Hold Time | 14 Days | 95 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $41.81, down 0.59% on the day, with a bearish technical signal driven by moving averages. The ETF focuses on international real estate across over 30 countries, offering a higher dividend yield than some peers but lagging in recent total returns. Short interest dropped 45.9% in September (Defense World, 2026-10-02), indicating reduced bearish bets, while the fund's expense ratio remains competitive at 0.12%.
Outlook: VNQI provides diversified global real estate exposure with income appeal, but faces headwinds from international market volatility and currency risks. The bearish technical trend and mixed sentiment suggest caution; long-term investors may value its yield and diversification, though near-term performance depends on global economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
